Cometriq (cabozantinib capsules) — Cigna
Non-Small Cell Lung Cancer
Initial criteria
- Patient is age ≥ 18 years
- Patient has recurrent, advanced, or metastatic disease
- Patient has RET gene rearrangement-positive tumor
- Patient has progressed on one of the first-line therapies, Gavreto (pralsetinib capsules) or Retevmo (selpercatinib capsules or tablets)
Approval duration
1 year